The RBD-based EIA provides a reliable, efficient platform for COVID-19 serological surveillance, suitable for both human and animal testing, and supports broader applications in vaccine evaluation and One Health monitoring.
Masangkay et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: